| Ident. | Authors (with country if any) | Title |
|---|
| 000029 (2020) |
Yu-Shi Zhang [République populaire de Chine] ; Wei-Hong Cong [République populaire de Chine] ; Jing-Jing Zhang [République populaire de Chine] ; Fei-Fei Guo [République populaire de Chine] ; Hong-Mei Li [République populaire de Chine] | [Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus]. |
| 000031 (2020) |
J. Reina [Espagne] | [Remdesivir, the antiviral hope against SARS-CoV-2]. |
| 000035 (2020) |
H. Li [République populaire de Chine] ; Y M Wang [République populaire de Chine] ; J Y Xu [République populaire de Chine] ; B. Cao [République populaire de Chine] | [Potential antiviral therapeutics for 2019 Novel Coronavirus]. |
| 000039 (2020) |
Kaijin Xu [République populaire de Chine] ; Hongliu Cai [République populaire de Chine] ; Yihong Shen [République populaire de Chine] ; Qin Ni [République populaire de Chine] ; Yu Chen [République populaire de Chine] ; Shaohua Hu [République populaire de Chine] ; Jianping Li [République populaire de Chine] ; Huafen Wang [République populaire de Chine] ; Liang Yu [République populaire de Chine] ; He Huang [République populaire de Chine] ; Yunqing Qiu [République populaire de Chine] ; Guoqing Wei [République populaire de Chine] ; Qiang Fang [République populaire de Chine] ; Jianying Zhou [République populaire de Chine] ; Jifang Sheng [République populaire de Chine] ; Tingbo Liang [République populaire de Chine] ; Lanjuan Li [République populaire de Chine] | [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. |
| 000040 (2020) |
X. Wang [République populaire de Chine] ; Y Q Ding [République populaire de Chine] | [From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment]. |
| 000091 (2020) |
Erwan Sallard [France] ; François-Xavier Lescure [France] ; Yazdan Yazdanpanah [France] ; France Mentre [France] ; Nathan Peiffer-Smadja [France] | Type 1 interferons as a potential treatment against COVID-19 |
| 000104 (2020) |
Sean Ekins [États-Unis] ; Thomas R. Lane [États-Unis] ; Peter B. Madrid [États-Unis] | Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond. |
| 000109 (2020) |
Inder P. Singh [Inde] ; Shiv Gupta [Inde] ; Sanjay Kumar [Inde] | Thiazole Compounds as Antiviral Agents: An Update. |
| 000123 (2020) |
Weilong Shang ; Yi Yang ; Yifan Rao ; Xiancai Rao | The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines |
| 000125 (2020) |
Yan-Rong Guo ; Qing-Dong Cao ; Zhong-Si Hong ; Yuan-Yang Tan ; Shou-Deng Chen ; Hong-Jun Jin ; Kai-Sen Tan [Singapour] ; De-Yun Wang [Singapour] ; Yan Yan | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status |
| 000138 (2020) |
Huilan Tu [République populaire de Chine] ; Sheng Tu [République populaire de Chine] ; Shiqi Gao [République populaire de Chine] ; Anwen Shao [République populaire de Chine] ; Jifang Sheng [République populaire de Chine] | The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event |
| 000139 (2020) |
Jin-Yan Li [République populaire de Chine] ; Zhi You [République populaire de Chine] ; Qiong Wang [République populaire de Chine] ; Zhi-Jian Zhou [République populaire de Chine] ; Ye Qiu [République populaire de Chine] ; Rui Luo [République populaire de Chine] ; Xing-Yi Ge [République populaire de Chine] | The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. |
| 000143 (2020) |
Yongshi Yang [République populaire de Chine] ; Fujun Peng [République populaire de Chine] ; Runsheng Wang [République populaire de Chine] ; Kai Guan [République populaire de Chine] ; Taijiao Jiang [République populaire de Chine] ; Guogang Xu [République populaire de Chine] ; Jinlyu Sun [République populaire de Chine] ; Christopher Chang [États-Unis] | The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China |
| 000147 (2020) |
Calvin J. Gordon [Canada] ; Egor P. Tchesnokov [Canada] ; Joy Y. Feng [États-Unis] ; Danielle P. Porter [États-Unis] ; Matthias Götte [Canada] | The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. |
| 000166 (2020) |
Yuxin Yan [République populaire de Chine] ; Woo In Shin [Malaisie] ; Yoong Xin Pang [République populaire de Chine] ; Yang Meng [République populaire de Chine] ; Jianchen Lai [République populaire de Chine] ; Chong You [République populaire de Chine] ; Haitao Zhao [États-Unis] ; Edward Lester [Royaume-Uni] ; Tao Wu [République populaire de Chine] ; Cheng Heng Pang [République populaire de Chine] | The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. |
| 000185 (2020) |
Rameez Jabeer Khan [Inde] ; Rajat Kumar Jha [Inde] ; Gizachew Muluneh Amera [Inde] ; Monika Jain [Inde] ; Ekampreet Singh [Inde] ; Amita Pathak [Inde] ; Rashmi Prabha Singh [Inde] ; Jayaraman Muthukumaran [Inde] ; Amit Kumar Singh [Inde] | Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase. |
| 000211 (2020) |
Robert Chunhua Zhao [République populaire de Chine] | Stem Cell-Based Therapy for Coronavirus Disease 2019. |
| 000257 (2020) |
Alice Lippi [Allemagne] ; Renato Domingues [Allemagne] ; Cristian Setz [Allemagne] ; Tiago F. Outeiro [Allemagne] ; Anita Krisko [Allemagne] | SARS-CoV-2: at the crossroad between aging and neurodegeneration. |
| 000261 (2020) |
Cheng-I Wu [Pays-Bas] ; Pieter G. Postema [Pays-Bas] ; Elena Arbelo ; Elijah R. Behr ; Connie R. Bezzina [Pays-Bas] ; Carlo Napolitano ; Tomas Robyns ; Vincent Probst ; Eric Schulze-Bahr ; Carol Ann Remme [Pays-Bas] ; Arthur A M. Wilde [Pays-Bas] | SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. |
| 000282 (2020) |
Markus Hoffmann [Allemagne] ; Hannah Kleine-Weber [Allemagne] ; Simon Schroeder [Allemagne] ; Nadine Krüger [Allemagne] ; Tanja Herrler [Allemagne] ; Sandra Erichsen [Autriche] ; Tobias S. Schiergens [Allemagne] ; Georg Herrler [Allemagne] ; Nai-Huei Wu [Allemagne] ; Andreas Nitsche [Allemagne] ; Marcel A. Müller [Russie] ; Christian Drosten [Allemagne] ; Stefan Pöhlmann [Allemagne] | SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. |
| 000286 (2020) |
Michele Costanzo ; Maria Anna Rachele De Giglio ; Giovanni Nicola Roviello | SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. |
